AUNA S.A. (AUNA) Form 6-K — Nov 17, 2026
Auna reported 3Q26 revenue of S/1,325 million, up 19% YoY as reported and 10% FX-neutral, with growth across all three markets. Adjusted EBITDA, however, fell 4.6% FX-neutral to S/231 million with a 17.5% margin, pressured by Colombia and Peru. The company cut its full-year 2026 Adjusted EBITDA guidance to 'broadly stable or slightly down' year-over-year, down from prior guidance of 10-14% FX-neutral growth, citing adverse medical costs under a terminated oncology risk-sharing contract in Colombia and government price caps on high-cost oncology drugs. Revenue guidance of 10-14% FX-neutral growth was reaffirmed.
Key figures
- Eps
- 0.27
- Revenue
- 1325000000
- Guidance
- FY26 revenue growth reaffirmed at 10-14% FX-neutral; Adjusted EBITDA revised down to broadly stable or slightly down YoY (from 10-14% FXN growth); capex ~4% of revenues
- Net Income
- 24000000
- Total Debt
- 3746000000
- Revenue Yoy
- 19% as reported / 10% FX-neutral
- Cash Position
- 614000000
- Surgeries q
- 23932
- Leverage ratio
- 3.5x
- Net debt pen m
- 3133
- Adjusted ebitda pen m
- 231
- Free cash flow ytd pen m
- 626
- Adjusted net income pen m
- 35
- Adjusted ebitda margin pct
- 17.5
- Free cash flow growth yoy pct
- 95
- Operating cash flow ytd pen m
- 713
- Operating cash flow growth yoy pct
- 62
- Mexico segment ebitda change lc pct
- 5
- Colombia segment ebitda change lc pct
- -30
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.